Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2016

01-04-2016 | Invited Review Article

Tumor angiogenesis—characteristics of tumor endothelial cells

Authors: Kyoko Hida, Nako Maishi, Chisaho Torii, Yasuhiro Hida

Published in: International Journal of Clinical Oncology | Issue 2/2016

Login to get access

Abstract

Tumor blood vessels provide nutrition and oxygen to the tumor, resulting in tumor progression. They also act as gatekeepers, inducing tumor metastasis. Thus, targeting tumor blood vessels is an important strategy in cancer therapy. Tumor endothelial cells (TECs), which line the inner layer of blood vessels of the tumor stromal tissue, are the main targets of anti-angiogenic therapy. Because new tumor blood vessels generally sprout from pre-existing vasculature, they have been considered to be the same as normal blood vessels. However, tumor blood vessels demonstrate a markedly abnormal phenotype that includes several important morphological changes. The degree of angiogenesis is determined by the balance between the angiogenic stimulators and inhibitors released by the tumor and host cells. Recent studies have revealed that TECs also exhibit altered characteristics which depend on the tumor microenvironment. Here, we review recent studies on TEC abnormalities and heterogeneity with respect to tumor progression and consider their therapeutic implications.
Literature
1.
2.
Folkman J, Kerbel R (2002) Role of angiogenesis in tumor growth and metastasis. Clinical translation of angiogenesis inhibitors. Semin Oncol 29(6 Suppl 16):15–18CrossRefPubMed
3.
Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273–286CrossRefPubMed
4.
Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191CrossRefPubMed
5.
Keedy VL, Sandler AB (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 98(12):1825–1830CrossRefPubMed
6.
Kindler HL, Friberg G, Singh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23(31):8033–8040CrossRefPubMed
7.
Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14(6):1860–1869CrossRefPubMed
8.
Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553–563PubMed
9.
Zhang L, Takara K, Yamakawa D, et al (2015) Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy. Cancer Sci 107(1):36–44
10.
Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410CrossRefPubMed
11.
Goh PP, Sze DM, Roufogalis BD (2007) Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 7(8):743–758CrossRefPubMed
12.
McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9(6):713–725CrossRefPubMed
13.
Hashizume H, Baluk P, Morikawa S et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4):1363–1380CrossRefPubMedPubMedCentral
14.
Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3(6):422–433CrossRefPubMed
15.
Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15(1):102–111CrossRefPubMed
16.
McDonald DM, Baluk P (2002) Significance of blood vessel leakiness in cancer. Cancer Res 62(18):5381–5385PubMed
17.
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62CrossRefPubMed
18.
Chang YS, di Tomaso E, McDonald DM et al (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97(26):14608–14613CrossRefPubMedPubMedCentral
19.
Langenkamp E, Molema G (2009) Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 335(1):205–222CrossRefPubMed
20.
Arap W, Kolonin MG, Trepel M et al (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121–127CrossRefPubMed
21.
Trepel M, Arap W, Pasqualini R (2002) In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 6(3):399–404CrossRefPubMed
22.
Hida K, Hida Y, Amin DN et al (2004) Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64(22):8249–8255CrossRefPubMed
23.
Arbiser JL, Raab G, Rohan RM et al (1999) Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am J Pathol 155(3):723–729CrossRefPubMedPubMedCentral
24.
Croix BS, Rago C, Velculescu V et al (2000) Genes expressed in human tumor endothelium. Science 289(5482):1197–1202CrossRef
25.
26.
Carson-Walter EB, Watkins DN, Nanda A et al (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61(18):6649–6655PubMed
27.
Nanda A, Croix BS (2004) Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 16(1):44–49CrossRefPubMed
28.
Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A et al (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25(7):852–861CrossRefPubMed
29.
Lu C, Bonome T, Li Y et al (2007) Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67(4):1757–1768CrossRefPubMed
30.
Hida K, Klagsbrun M (2005) A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65(7):2507–2510CrossRefPubMed
31.
Amin DN, Hida K, Bielenberg DR et al (2006) Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 66(4):2173–2180CrossRefPubMed
32.
Tsuchiya K, Hida K, Hida Y et al (2010) Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol 36(6):1379–1386PubMed
33.
Matsuda K, Ohga N, Hida Y et al (2010) Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 394(4):947–954CrossRefPubMed
34.
Kurosu T, Ohga N, Hida Y et al (2011) HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 104(5):819–829CrossRefPubMedPubMedCentral
35.
Bussolati B, Deambrosis I, Russo S et al (2003) Altered angiogenesis and survival in human tumor-derived endothelial cells. Faseb J 17(9):1159–1161PubMed
36.
Matsuda K, Ohga N, Hida Y, et al (2010) Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 394(4):947–954
37.
Bussolati B, Grange C, Bruno S et al (2006) Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp Cell Res 312(6):913–924CrossRefPubMed
38.
Fonsato V, Buttiglieri S, Deregibus MC et al (2006) Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis. Am J Pathol 168(2):706–713CrossRefPubMedPubMedCentral
39.
Akino T, Hida K, Hida Y et al (2009) Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 175(6):2657–2667CrossRefPubMedPubMedCentral
40.
Ricci-Vitiani L, Pallini R, Biffoni M et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325):824–828CrossRefPubMed
41.
Wang R, Chadalavada K, Wilshire J et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833CrossRefPubMed
42.
Xiong YQ, Sun HC, Zhang W et al (2009) Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15(15):4838–4846CrossRefPubMed
43.
Akiyama K, Ohga N, Hida Y et al (2012) Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 180(3):1283–1293CrossRefPubMed
44.
Mundhekar AN, Bullard DC, Kucik DF (2006) Intracellular heterogeneity in adhesiveness of endothelium affects early steps in leukocyte adhesion. Am J Physiol Cell Physiol 291(1):C130–C137CrossRefPubMed
45.
Molema G (2010) Heterogeneity in endothelial responsiveness to cytokines, molecular causes, and pharmacological consequences. Semin Thromb Hemost 36(3):246–264CrossRefPubMed
46.
Saubamea B, Cochois-Guegan V, Cisternino S et al (2012) Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression. J Cereb Blood Flow Metab 32(1):81–92CrossRefPubMedPubMedCentral
47.
48.
Ohga N, Ishikawa S, Maishi N et al (2012) Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am J Pathol 180(3):1294–1307CrossRefPubMed
49.
Bussolati B, Assenzio B, Deregibus MC et al (2006) The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med (Berl) 84(10):852–863CrossRef
50.
Adya R, Tan BK, Punn A et al (2008) Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3 K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78(2):356–365CrossRefPubMed
51.
Naito H, Kidoya H, Sakimoto S et al (2011) Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels. EMBO J 31(4):842–855CrossRefPubMedPubMedCentral
52.
Ohmura-Kakutani H, Akiyama K, Maishi N et al (2014) Identification of tumor endothelial cells with high aldehyde dehydrogenase activity and a highly angiogenic phenotype. PLoS One 9(12):e113910CrossRefPubMedPubMedCentral
53.
Sato Y (2011) Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Cancer Sci 102(7):1253–1256CrossRefPubMed
54.
Helfrich I, Scheffrahn I, Bartling S et al (2010) Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207(3):491–503CrossRefPubMedPubMedCentral
55.
Taylor SM, Nevis KR, Park HL et al (2010) Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels. Blood 116(16):3108–3117CrossRefPubMedPubMedCentral
56.
Gao D, Nolan D, McDonnell K, et al (2009) Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796(1):33–40
Metadata
Title
Tumor angiogenesis—characteristics of tumor endothelial cells
Authors
Kyoko Hida
Nako Maishi
Chisaho Torii
Yasuhiro Hida
Publication date
01-04-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0957-1

Other articles of this Issue 2/2016

International Journal of Clinical Oncology 2/2016 Go to the issue

Original Article

Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes

Original Article

Growth rate of chemotherapy-naïve lung metastasis from colorectal cancer could be a predictor of early relapse after lung resection

Original Article

R.E.N.A.L. nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy

Introduction to Invited Review Articles

Development and future directions of antiangiogenic therapy in hepatocellular carcinoma

Original Article

Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients

Original Article

Relationship between quality of life instruments and phonatory function in tracheoesophageal speech with voice prosthesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits